Liraglutide biosimilar(Tai-Tianqing)

利拉鲁肽生物类似药（正大天晴）

Report date: 2024/06/25 17:34:10

Base Information

Drug NameLiraglutide biosimilar(Tai-Tianqing)
Drug Alias NameTQZ-2451
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2024/06/18
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdState Pharmaceutical Administration of Shanghai Institute of Pharmaceutical IndustryLianyungang Runzhong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesState Pharmaceutical Administration of Shanghai Institute of Pharmaceutical IndustryLianyungang Runzhong Pharmaceutical Co Ltd
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A